FrancophonIA/ELRC3.0 huggingface dataset:
English: Duloxetine Mylan is used to treat adults with the following diseases:
Estonian: Duloxetine Mylani kasutatakse järgmiste haiguste raviks täiskasvanutel:
English: The European Commission granted a marketing authorisation valid throughout the European Union for Duloxetine Mylan on 19 June 2015.
Estonian: Euroopa Komisjon andis Duloxetine Mylani müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. juunil 2015.
English: What measures are being taken to ensure the safe and effective use of Duloxetine Mylan?
Estonian: Mis meetmed võetakse, et tagada Duloxetine Mylani ohutu ja efektiivne kasutamine?
English: The Committee recommended that Duloxetine Mylan be approved for use in the EU.
Estonian: Komitee soovitas Duloxetine Mylani kasutamise Euroopa Liidus heaks kiita.
English: Duloxetine Mylan is available as gastroresistant capsules (30 and 60 mg).
Estonian: Duloxetine Mylani turustatakse gastroresistentsete kapslitena (30 ja 60 mg).
English: It works by preventing the neurotransmitters serotonin (5-hydroxytryptamine) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord.
Estonian: See pärsib neurotransmitterite serotoniini (5-hüdroksütrüptamiin) ja noradrenaliini tagasihaaret pea- ja seljaaju närvirakkudesse.
English: For major depression, the recommended dose of Duloxetine Mylan is 60 mg once a day.
Estonian: Raske depressiooni raviks on Duloxetine Mylani soovituslik annus 60 mg üks kord ööpäevas.
English: This is a summary of the European public assessment report (EPAR) for Duloxetine Mylan.
Estonian: See on ravimi Duloxetine Mylan Euroopa avaliku hindamisaruande kokkuvõte.
English: In patients who respond to Duloxetine Mylan, treatment should continue for several months, to prevent the disorder coming back.
Estonian: Patsiendid, kellel tekib Duloxetine Mylanile ravivastus, peavad jätkama ravimi võtmist mitu kuud, et ennetada haiguse taastumist.
English: For diabetic neuropathic pain, the recommended dose is 60 mg per day but some patients may need a higher dose of 120 mg per day.
Estonian: Diabeetilise neuropaatilise valu raviks on soovitatav annus 60 mg üks kord ööpäevas, kuid mõnel patsiendil võib olla vaja suuremat annust 120 mg ööpäevas.
English: Because Duloxetine Mylan is a generic medicine of Cymbalta, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Duloxetine Mylan on Cymbalta geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: What is Duloxetine Mylan and what is it used for?
Estonian: Mis on Duloxetine Mylan ja milleks seda kasutatakse?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Duloxetine Mylan, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Duloxetine Mylani omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Duloxetine Mylan has been shown to have comparable quality and to be bioequivalent to Cymbalta.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Duloxetine Mylan võrreldav kvaliteet ja bioekvivalentsus ravimiga Cymbalta.
English: Duloxetine Mylan contains the active substance duloxetine and is a ‘generic medicine'.
Estonian: Duloxetine Mylan sisaldab toimeainena duloksetiini ja on geneeriline ravim.
English: Duloxetine Mylan duloxetine
Estonian: Duloxetine Mylan duloksetiin
English: For generalised anxiety disorder, the recommended starting dose is 30 mg once a day, but the dose can be increased to 60, 90 or 120 mg depending on the patient's response.
Estonian: Generaliseerunud ärevushäire raviks on soovitatav algannus 30 mg üks kord ööpäevas, kuid annust võib olenevalt patsiendi ravivastusest suurendada 60, 90 või 120 mg-ni. Enamik patsiente vajab ravimit annuses 60 mg ööpäevas.
English: This means that Duloxetine Mylan is similar to a ‘reference medicine' already authorised in the European Union (EU) called Cymbalta.
Estonian: See tähendab, et Duloxetine Mylan on sarnane võrdlusravimiga Cymbalta, millel juba on Euroopa Liidus müügiluba.
English: For practical information about using Duloxetine Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Duloxetine Mylani kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Other information about Duloxetine Mylan
Estonian: Muu teave Duloxetine Mylani kohta
English: For more information about treatment with Duloxetine Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Duloxetine Mylaniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In patients who respond to Duloxetine Mylan, treatment should continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past.
Estonian: peavad jätkama ravimi võtmist mitu kuud, et ennetada haiguse taastumist; samuti peavad ravimi võtmist jätkama patsiendid, kellel on varem olnud korduvaid depressiooniepisoode.
English: The active substance in this medicine, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor.
Estonian: Duloxetine Mylani toimeaine duloksetiin on serotoniini ja noradrenaliini tagasihaarde inhibiitor.
English: The dose of Duloxetine Mylan should be reduced gradually when stopping treatment.
Estonian: Ravi katkestamisel tuleb Duloxetine Mylani annust vähendada järk-järgult.
English: Therefore, the CHMP's view was that, as for Cymbalta, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Cymbalta korral, ületab ravimi Duloxetine Mylan kasulikkus sellega kaasnevad riskid.
English: It is not intended to provide practical advice on how to use Duloxetine Mylan.
Estonian: Hindamisaruandes ei anta Duloxetine Mylani kasutamise praktilisi nõuandeid.
English: Because Duloxetine Mylan is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Cymbalta.
Estonian: Et Duloxetine Mylan on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Duloxetine Mylani bioekvivalentsust võrdlusravimiga Cymbalta.
English: Why is Duloxetine Mylan approved?
Estonian: Miks Duloxetine Mylan heaks kiideti?
English: How is Duloxetine Mylan used?
Estonian: Kuidas Duloxetine Mylani kasutatakse?
English: How has Duloxetine Mylan been studied?
Estonian: Kuidas Duloxetine Mylani uuriti?
English: How does Duloxetine Mylan work?
Estonian: Kuidas Duloxetine Mylan toimib?
English: What are the benefits and risks of Duloxetine Mylan?
Estonian: Milles seisneb Duloxetine Mylani kasulikkus ja mis riskid ravimiga kaasnevad?
English: It is used in the following ways:
Estonian: Seda kasutatakse järgmistel viisidel:
English: Other common side effects include psychiatric disorders such as agitation, excitedness, aggression, nervousness, depression and paranoid reactions, as well as reduced consciousness and confusion.
Estonian: Teised sagedad kõrvalnähud on muu hulgas psühhiaatrilised häired, näiteks agitatsioon, erutus, agressiivsus, närvilisus, depressioon ja paranoidsed reaktsioonid, samuti teadvusehäired ja segasus.
English: Vigabatrin should not be used in patients who already have visual field defects.
Estonian: Vigabatriini ei tohi kasutada patsiendid, kellel on juba nägemisvälja defektid.
English: Because the effects on vision can lead to blindness, vigabatrin should only be used after careful assessment of possible alternatives, and patients' vision must be regularly tested during treatment.
Estonian: Kuna nägemishäired võivad põhjustada pimedust, tohib vigabatriini kasutada üksnes pärast võimalike alternatiivide hoolikat kaalumist ning patsientide nägemist tuleb ravi ajal korrapäraselt kontrollida.
English: What measures are being taken to ensure the safe and effective use of Kigabeq?
Estonian: Mis meetmed võetakse, et tagada Kigabeqi ohutu ja efektiivne kasutamine?
English: Further information on Kigabeq can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Kigabeqi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Kigabeq is only used in partial epilepsy when patients have already tried all other appropriate treatments or cannot use them because of side effects.
Estonian: Kigabeqi kasutatakse partsiaalse epilepsia raviks üksnes juhul, kui patsiendid on juba proovinud kõiki muid sobivaid raviviise või ei saa neid kasutada kõrvalnähtude tõttu.
English: Kigabeq (vigabatrin)
Estonian: Kigabeq (vigabatriin)
English: The medicine is available as soluble tablets of 100 or 500 mg, with a score-line so they can be halved.
Estonian: Ravimit turustatakse 100 või 500 mg lahustuvate tablettidena, millel on poolitusjoon.
English: The tablets are dissolved in water to make a solution for the patient to drink.
Estonian: Tabletid lahustatakse vees ja lahus antakse patsiendile joomiseks.
English: Therefore, the Agency's view was that, as for Sabril, Kigabeq's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Seetõttu oli amet arvamusel, et nagu ka Sabrili korral, on Kigabeqi kasulikkus suurem kui sellega kaasnevad riskid ja seda võib kasutada ELis.
English: The dose depends on the condition being treated and the patient's body weight, and is adjusted according to the patient's response to treatment.
Estonian: Annus sõltub ravitavast haigusseisundist ja patsiendi kehakaalust ning seda kohandatakse vastavalt patsiendi ravivastusele.
English: Kigabeq is a medicine for treating epilepsy in children between 1 month and 7 years of age.
Estonian: Kigabeq on ravim, mida kasutatakse epilepsia raviks 1-kuulistel kuni 7-aastastel lastel.
English: GABA reduces the electrical activity of the brain.
Estonian: GABA vähendab aju elektrilist talitlust.
English: The company provided information from the published literature on the benefits and risks of vigabatrin in the approved uses.
Estonian: Ettevõte esitas teaduskirjandusest pärit teabe vigabatriini kasulikkuse ja riskide kohta heakskiidetud näidustustel.
English: • together with other medicines to treat partial epilepsy (seizures affecting one part of the brain), including when the seizures spread to other parts of the brain and become more generalised.
Estonian: • koos teiste ravimitega partsiaalse epilepsia (epilepsiahood, mis haaravad üht ajuosa) raviks, sealhulgas juhul, kui epilepsiahood levivad teistesse ajuosadesse ja generaliseeruvad.
English: The reference medicine for Kigabeq is Sabril (500 mg granules).
Estonian: Kigabeqi võrdlusravim on Sabril (500 mg graanulid).
English: What is Kigabeq and what is it used for?
Estonian: Mis on Kigabeq ja milleks seda kasutatakse?
English: • on its own to treat infantile spasms (West syndrome), a rare epilepsy disorder that starts at a very young age, usually in the first few months of life;
Estonian: • ainuravimina infantiilsete spasmide (Westi sündroom - harvaesinev epilepsiavorm, mis algab väga varases eas, tavaliselt esimestel elukuudel) raviks;
English: The most common side effects with vigabatrin (which may affect more than 1 in 10 people) are visual field defects (effects on vision), tiredness, sleepiness and joint pains.
Estonian: Vigabatriini kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on nägemisvälja defektid (nägemishäired), väsimus, unisus ja liigesevalu.
English: Rarely there may be effects on the retina (the light-sensing layer at the back of the eye), encephalopathy (brain damage) or attempts at suicide.
Estonian: Harva võib esineda toimeid võrkkestale (valgustundlik kiht silmapõhjas), entsefalopaatiat (ajukahjustus) või enesetapukatseid.
English: Blocking the enzyme that breaks it down increases the amount of GABA present in the brain, and so increases its effect.
Estonian: GABA-t lagundava ensüümi blokeerimine suurendab ajus oleva GABA hulka ja seeläbi suurendab selle toimet.
English: This means that it is similar to a ‘reference medicine' containing the same active substance, but Kigabeq is available in a different form and strengths.
Estonian: See tähendab, et see on sarnane sama toimeainet sisaldava võrdlusravimiga, kuid Kigabeqi turustatakse muu ravimvormina ja teistes tugevustes.
English: Side effects reported with Kigabeq are carefully evaluated and any necessary action taken to protect patients.
Estonian: Kigabeqi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: This helps suppress the abnormal electrical activity that leads to infantile spasms and partial epilepsy, and so controls the symptoms of these conditions.
Estonian: omakorda aitab pärssida infantiilseid spasme ja partsiaalset epilepsiat põhjustavat ebanormaalset elektrilist talitlust ning seeläbi nende haigusseisundite sümptomeid kontrolli all hoida.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kigabeq have been included in the summary of product characteristics and the package leaflet.
Estonian: Kigabeqi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Other information about Kigabeq
Estonian: Muu teave Kigabeqi kohta
English: For more information about using Kigabeq, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Kigabeqi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The European Medicines Agency decided that in accordance with EU requirements, Kigabeq has been shown to have comparable quality and to be bioequivalent to Sabril.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt ELi nõuetele on tõendatud Kigabeqi võrreldav kvaliteet ja bioekvivalentsus ravimiga Sabril.
English: What are the risks associated with Kigabeq?
Estonian: Mis riskid Kigabeqiga kaasnevad?
English: As for all medicines, data on the use of Kigabeq are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Kigabeqi kasutamise kohta pidevat järelevalvet.
English: The active substance in Kigabeq, vigabatrin, blocks the action of an enzyme called GABA transaminase, which breaks down a substance in the brain called GABA (gamma aminobutyric acid).
Estonian: Kigabeqi toimeaine vigabatriin blokeerib aju virgatsainet GABA (gamma-aminovõihapet) lagundava ensüümi GABA-transaminaasi toime.
English: As for every medicine, the company provided studies on the quality of Kigabeq.
Estonian: Nagu iga ravimi korral, esitas ettevõte Kigabeqi kvaliteedi uuringud.
English: Kigabeq contains the active substance vigabatrin and is a ‘hybrid medicine'.
Estonian: Kigabeq sisaldab toimeainena vigabatriini ja on hübriidravim.
English: It also carried out a study that showed that Kigabeq is bioequivalent to the reference medicine, Sabril.
Estonian: Ettevõte tegi ka uuringu, mis näitas, et Kigabeq on bioekvivalentne võrdlusravimiga Sabril.
English: For the full list of side effects and restrictions with Kigabeq, see the package leaflet.
Estonian: Kigabeqi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: In patients who cannot drink it can be given by a tube into the stomach.
Estonian: Kui patsient ei ole võimeline jooma, tohib lahust manustada maosondi kaudu.
English: How does Kigabeq work?
Estonian: Kuidas Kigabeq toimib?
English: Kigabeq can only be obtained with a prescription and treatment must started and supervised by a doctor specialising in the treatment of epilepsy or nervous system disorders.
Estonian: Ravi peab algama ja toimuma epilepsia või närvisüsteemihäirete ravile spetsialiseerunud arsti järelevalve all.
English: How is Kigabeq used?
Estonian: Kuidas Kigabeqi kasutatakse?
English: An overview of Kigabeq and why it is authorised in the EU
Estonian: Ülevaade ravimist Kigabeq ja ELis müügiloa väljastamise põhjendus
English: What benefits of Kigabeq have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Kigabeqi kasulikkus?
English: The horses should be revaccinated every year.
Estonian: Hobuseid tuleb igal aastal uuesti vaktsineerida.
English: The withdrawal period is zero days.
Estonian: Keeluaeg on 0 päeva.
English: This summary was last updated on 05/08/2011.
Estonian: Kokkuvõtte viimane uuendus: 05/08/2011
English: In all studies the vaccinated horses were compared with horses that were not vaccinated.
Estonian: Kõikides uuringutes võrreldi vaktsineeritud hobuseid vaktsineerimata hobustega.
English: They may also have a temporary swelling at the injection site which usually disappears within four days.
Estonian: Süstekohale võib tekkida ajutine turse, kuid tavaliselt kaob see nelja päeva jooksul.
English: Protection starts four weeks after the first injection and lasts for a year.
Estonian: Immuunsus tekib neli nädalat pärast esimest süsti ja püsib 1 aasta.
English: The first injection is given from five months of age and the second injection is given four to six weeks later.
Estonian: Esimene süst tehakse vähemalt 5 kuu vanustele loomadele ja teine 4-6 nädalat hiljem.
English: The vaccine was tested in nine laboratory studies in horses from five months of age.
Estonian: Vaktsiini katsetati üheksas laboriuuringus vähemalt 5 kuu vanustel hobustel.
English: The vaccine also contains an ‘adjuvant' to enhance the immune response.
Estonian: Vaktsiin sisaldab parema immuunvastuse saamiseks ka adjuvanti.
English: What are the precautions for the person who gives the medicine or comes into contact with the animal?
Estonian: Mis ettevaatusmeetmeid peab võtma loomale vaktsiini andev või loomaga kokku puutuv inimene?
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Proteq West Nile to MERIAL on 05/08/2011.
Estonian: Euroopa Komisjon andis vaktsiini Proteq West Nile müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele MERIAL 05/08/2011.
English: The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption or eggs or milk used for human consumption.
Estonian: Keeluaeg on alates ravimi manustamisest arvestatav ajavahemik, mille jooksul ei tohi looma/lindu tappa ega tema liha, mune või piima tarvitada toiduks.
English: If someone accidentally injects themselves with the medicine, the person should seek medical advice immediately and show the package leaflet or label to the doctor.
Estonian: Juhusliku endale süstimise korral tuleb pöörduda kohe arsti poole ja näidata talle vaktsiini pakendi infolehte või etiketti.
English: Horses vaccinated with Proteq West Nile may have a slightly raised body temperature (up to 1.5°C) lasting up to two days.
Estonian: Pärast Vaktsiiniga Proteq West Nile vaktsineerimist võib hobuste kehatemperatuur kergelt tõusta (kuni 1,5 °C) kuni kahe päeva jooksul.
English: The vaccine is given to young horses as two injections into the neck muscles.
Estonian: Vaktsiini manustatakse noortele hobustele kahe süstina kaelalihasesse.
English: The studies showed that the vaccine prevents viraemia in horses and reduces clinical signs in horses infected with West Nile virus.
Estonian: Uuringud näitasid, et vaktsiin ennetab vireemiat ja leevendab haiguse kliinilisi sümptomeid LääneNiiluse viirusega nakatunud hobustel.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) considered that Proteq West Nile is generally well tolerated and useful in reducing clinical outbreaks of West Nile disease.
Estonian: Veterinaarravimite komitee otsustas, et ravimit Proteq West Nile talutakse üldiselt hästi ja see on kasulik Lääne-Niiluse haiguse puhangute vähendamisel.
English: When a horse is given the vaccine, the immune system recognises the West Nile proteins PreM and E as ‘foreign' and makes antibodies against it.
Estonian: Kui hobusele manustatakse vaktsiini, peab immuunsüsteem Lääne-Niiluse viiruse PreM- ja E-valke võõraks ja tekitab nende vastu antikehi.
English: Proteq West Nile is used to protect horses from 5 months of age against West Nile disease.
Estonian: Vaktsiini Proteq West Nile kasutatakse vähemalt 5 kuu vanuste hobuste kaitseks Lääne-Niiluse haiguse eest.
English: Proteq West Nile is a vaccine.
Estonian: Proteq West Nile on vaktsiin.
English: The main measure of effectiveness was based on the number of horses who had viraemia or clinical signs of West Nile disease.
Estonian: Efektiivsuse põhinäitaja oli vireemia või Lääne-Niiluse haiguse kliiniliste tundemärkidega hobuste arv.
English: Proteq West Nile is a vaccine that contains West Nile recombinant canarypox virus (vCP2017 virus).
Estonian: Proteq West Nile on vaktsiin, mis sisaldab Lääne-Niiluse viiruse geenidega rekombineeritud kanaarilinnurõugeviirust (vCP2017).
English: What is Proteq West Nile?
Estonian: Mis on Proteq West Nile?
English: West Nile recombinant canarypox virus (vCP2017 virus)
Estonian: Lääne-Niiluse viiruse geenidega rekombineeritud kanaarilinnurõugeviirus (vCP2017)
English: The CVMP therefore concluded that the benefits of Proteq West Nile exceed the risks for the vaccination of horses from 5 months of age against West Nile disease and recommended that Proteq West Nile be given a marketing authorisation.
Estonian: Seetõttu otsustas veterinaarravimite komitee, et vähemalt 5 kuu vanuste hobuste vaktsineerimisel Lääne-Niiluse haiguse vastu on vaktsiini Proteq West Nile kasulikkus suurem kui sellega kaasnevad riskid, ning soovitas anda vaktsiini Proteq West Nile müügiloa.
English: For a full list of the side-effects reported with Proteq West Nile, see the package leaflet.
Estonian: Vaktsiini Proteq West Nile kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The vaccine strain vCP2017 in Proteq West Nile is a ‘carrier' canarypox virus that has been given a gene that makes it able to produce part of the West Nile virus, the proteins PreM and E. The canarypox viruses do not spread or multiply in the vaccinated horses.
Estonian: Vaktsiinis Proteq West Nile sisalduv tüvi vCP2017 on kanaarilinnurõugeviirus, millele on lisatud geen, mille tõttu suudab tüvi tekitada Lääne-Niiluse viiruse osi, PreM- ja E-valke.
English: Why has Proteq West Nile been approved?
Estonian: Miks Proteq West Nile heaks kiideti?
English: West Nile disease is a mosquito-borne viral disease that can cause encephalitis (inflammation of the brain) and meningitis (inflammation of the lining of the brain and spinal cord).The vaccine is used to reduce the number of horses with the West Nile virus in their blood (viraemia) or with clinical signs of the disease.
Estonian: Lääne-Niiluse haigus on sääskedega edasikanduv viirushaigus, mis võib põhjustada entsefaliiti (peaajupõletik) ja meningiiti (pea- ja seljaaju kelmete põletik).
English: Other information about Proteq West Nile:
Estonian: Muu teave vaktsiini Proteq West Nile kohta
English: How does Proteq West Nile work?
Estonian: Kuidas Proteq West Nile toimib?
English: What is the risk associated with Proteq West Nile?
Estonian: Mis riskid vaktsiiniga Proteq West Nile kaasnevad?
English: How has Proteq West Nile been studied?
Estonian: Kuidas vaktsiini Proteq West Nile uuriti?
English: In the future, the immune system will be able to produce antibodies more quickly when it is exposed to West Nile virus, and this helps to protect against mortality due to West Nile disease.
Estonian: Kui immuunsüsteem puutub hiljem kokku Lääne-Niiluse viirusega uuesti, tekivad antikehad kiiremini.
English: What benefit has Proteq West Nile shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Proteq West Nile kasulikkus?
English: What is Proteq West Nile used for?
Estonian: Milleks vaktsiini Proteq West Nile kasutatakse?